Author： Overman Michael Kopetz Scott Varadhachary Gauri Fukushima Masakazu Kuwata Keizo Mita Akira Wolff Robert Hoff Paulo Xiong Henry Abbruzzese James
Publisher： Informa Healthcare
ISSN： 0735-7907
Source： Cancer Investigation, Vol.26, Iss.8, 2008-10, pp. : 794-799
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
TAS-102 is a novel formulation of the fluorinated pyrimidine analogue trifluorothymidine (FTD) with an inhibitor of thymidine phosphorylase. The purpose of this study was to determine the MTD and DLT for TAS-102 administered three times a day on days 1-5 and 8-12 every 4 weeks. Fifteen patients were enrolled with two patients experiencing dose-limiting fatigue and granulocytopenia at the first dose level (80 mg/m2/day). Granulocytopenia was the primary toxicity: 7 patients experienced grade 3 or 4 granulocytopenia with the first course. No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population.
Related content
By Saif Muhammad Sellers Sandra Li Mao Wang Wei Cusimano Linda Wang Hui Zhang Ruiwen
Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 6, 2007-11 ,pp. :
Access to resources
Recommend
By Crul M. Rosing H. de Klerk G.J. Dubbelman R. Traiser M. Reichert S. Knebel N.G. Schellens J.H.M. Beijnen J.H. ten Bokkel Huinink W.W.
European Journal of Cancer, Vol. 38, Iss. 12, 2002-08 ,pp. :
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
By Plummer Ruth Madi Ayman Jeffels Melinda Richly Heike Nokay Bahar Rubin Stephen Ball Howard Weller Steve Botbyl Jeffrey Gibson Diana Scheulen Max
Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. :
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. :